TXMD - TherapeuticsMD rises 22% on strong Q2 result as Annovera sales rise

• Therapeutics MD ( NASDAQ: TXMD ) is trading 22% higher after the company posted a 24%rise in revenue, helped by strong sales of Annovera.
• The company posted Revenue of $28.6M, while Q2 GAAP EPS was $12.39.
• Vaginal ring Annovera net product revenue rose 91% Y/Y to $18.3M for the quarter.
• Total operating expense decreased 21% Y/Y to $42.7M.
• As of June 30, the company had cash of $26.3M, compared with $65.1M.
• Over 13,000 healthcare providers prescribed Annovera during the quarter, of which 1,487 were new writers.
• Imvexxy net product revenue was $6.7M, from 9.8M, a year earlier.
• Presentation , Transcript

For further details see: